Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2013, vol. 22, nr 1, January-February, p. 5–15

Publication type: editorial article

Language: English

New Prognostic Factors in Breast Cancer

Nowe czynniki prognostyczne w raku piersi

Adam Maciejczy1,K

1 Department of Teleradiotherapy, Lower Silesian Oncology Center Wrocław, Poland

Abstract

For many years, the age of the patient, the condition of axillar lymph nodes, the size of the tumour, histological traits (in particular histological grade of malignancy and invasion of lymphatic vessels), condition of hormonal receptors and HER2 represented principal factors used for the stratification of breast cancer patients for the purposes of evaluating the prognosis and determining the appropriate strategy of treatment. Although the variables are useful for the prognostic evaluation of individual groups of breast cancer patients, their role in determining the individual risk level of the patient and in the selection of supplementary treatment is quite restricted. This article shows the prognostic value of additional parameters, whose expression is associated with chemioresistance (MRP2, BCRP, YB1) or individual assessment of the dynamics of tumor progression (S100P, BUBR1). In addition, it describes the role of an online database of “The Kaplan-Meier plotter” which contains the assessment of the effects of expression of various genes on the clinical outcome of patients with breast cancer.

Streszczenie

Od wielu lat wiek pacjenta, stan pachowych węzłów chłonnych, wielkość guza, cechy histologiczne (zwłaszcza histologiczny stopień złośliwości i inwazja naczyń limfatycznych), stan receptorów hormonalnych oraz HER2 są głównymi czynnikami stosowanymi do stratyfikacji pacjentów z rakiem piersi w celu oceny rokowania i określenia odpowiedniego sposobu leczenia. Chociaż te dane są bardzo przydatne do oceny rokowniczej poszczególnych grup pacjentów chorych na raka piersi, to jednak ich rola w określaniu indywidualnego poziomu ryzyka progresji choroby oraz w doborze dedykowanego sposobu leczenia uzupełniającego jest ograniczona. W artykule przedstawiono wartość prognostyczną dodatkowych parametrów, których ekspresja jest wiązana z chemioopornością guza (MRP2, YB1) lub indywidualną oceną ryzyka progresji zmiany nowotworowej (S100P, BUBR1). Dodatkowo opisano rolę bazy danych „The Kaplan-Meier plotter”, zawierającej oceny wpływu ekspresji różnych genów na wyniki kliniczne chorych na raka piersi.

Key words

breast cancer, prognostic factors, chemoresistance, KMplotter.

Słowa kluczowe

rak piersi, czynniki prognostyczne, chemiooporność, KMplotter.

References (37)

  1. Schnitt S: Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Modern Pathol 2010, 23, 60–64.
  2. Niemiec J, Ryś J: Basal subtype of breast cancer: a morbid unit of a specific immunophenotypic characteristics [in Polish]. Pol J Pathol 2011, 4, 36–44.
  3. Olszewski W, Chmielik E, Rys J: Pathomorphological selection of patients to systemic therapy [in Polish]. Pol J Pathol 2011, 4, 4, 28–33.
  4. Rakha E, Reis-Filho J, Baehner F, Dabbs D, Decker T, Eusebi V, Fox S, Ichihara S, Jacquemier J, Lakhani S, Palacios J, Richardson A, Schnitt S, Schmitt F, Tan P-H, Tse G, Badve S, Ellis I: Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010, 12, 207, 2–12.
  5. Zmorzyński S, Karczmarek-Borowska B, Filip A: Molecular markers of carcinogenesis employed in diagnosis and planning of therapy in breast cancer. Współ Onkol 2008, 12, 5, 205–211.
  6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000, 406, 6797, 747–752.
  7. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield M, Hayes D, Bast Jr R: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25, 5287–5312.
  8. Burstein H, Prestrud A, Seidenfeld J, Anderson H, Buchholz T Davidson N, Gelmon K, Giordano S, Hudis C, Malin J, Mamounas E, Rowden D, Solky A, Sowers M, Stearns V, Winer E, Somerfield M, Griggs J: American Society of Clinical Oncology Clinical Practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 28, 3784–3796.
  9. Dębska S, Owecka A, Czernek U, Szydłowska-Pazera K, Habib M, Potemski P: Transmembrane transporters ABCC – structure, function and role in multidrug resistance of cancer cells. Postepy Hig Med Dosw 2011, 65, 552–561.
  10. Bradshaw DM, Arceci RJ: Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998, 16, 3674–3690.
  11. Lenart K, Szyda A, Kielbasinski M, Dus D, Podolak-Dawidziak M: Clinical effects of multidrug resistance in neoplasms. Onkol Prakt Klin 2005, 1, 1, 18–26.
  12. Sharom FJ: ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008, 9, 105–127.
  13. Leonard G, Fojo T, Bates S: The role of ABC transporters in clinical practice. Oncologist 2003, 8, 411–424.
  14. Wind N, Holen I: Multidrug resistance in breast cancers: from in vitro models to clinical studies. Int J Breast Cancer 2011, 1–12.
  15. Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornafel J, Wojnar A, Pudelko M, Dietel M, Denkert C, Zabel M, Lage H: Relationship between the expression of cyclooxygenase 2 and MDR1/Pglycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res 2005, 7, 5, 862–870.
  16. Trock BJ, Leonessa F, Clarke R: Multidrug resistance in breast cancer: a meta-analysis MDR1/gp170 expression and its possibile functional significance. J Natl Cancer Inst 1997, 89, 917–931.
  17. Burger H, Foekens JA, Look MP et al.: RNA expression of breast cancer resistance protein, lung resistancerelated protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with hemotherapeutic response. Clin Cancer Res 2003, 9, 827–836.
  18. Takahashi K, Shibata T, Oba T, Ishikawa T, Yoshikawa M, Tatsunami R, Takahashi K, Tampo Y: Multidrugresistance-associated protein plays a protective role in menadione-induced oxidative stress in endothelial cells. Life Sci 2009, 84, 211–217.
  19. Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F: The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr Drug Targets 2006, 7, 893–909.
  20. Atalay C, Demirkazik A, Gunduz U: Role of ABCB1 and ABCC1 gene induction on survival in locally advanced breast cancer. J Chemother 2008, 20, 734–739.
  21. Deeley RG, Westlake C, Cole SP: Transmembrane transport of endoand xenobiotics by mammalian ATPbinding cassette multidrug resistance proteins. Physiol Rev 2006, 86, 849–899.
  22. Nooter K, Brutel de la Riviere G, Look MP: The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 1997, 76, 4, 486–493.
  23. Maciejczyk A, Jagoda E, Wysocka T, Matkowski R, Györffy B, Lage H, Surowiak P: ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome. Pathol Oncol Res 2012 Apr, 18(2), 331–342.
  24. Materna V, Kaplenko I, Spaczynski M, Dolinska-Krajewska B, Gebarowska E, Dietel M, Zabel M, Lage H: ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res 2006, 12, 23, 7149–7158.
  25. Maciejczyk A, Szelachowska J, Ekiert M, Matkowski R, Hałoń A, Surowiak P: Analysis of BCRP expression in breast cancer patients. Ginekol Pol 2012, 83, 9, 681–687.
  26. Maciejczyk A, Szelachowska J, Ekiert M, Matkowski R, Hałoń A, Lage H, Surowiak P: Elevated nuclear YB1 expression is associated with poor survival of patients with early breast cancer. Anticancer Res 2012, 32, 8, 3177– 3184.
  27. Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, Royer H-D, Eckstein N, Mohrmann S, Ting E, Kiechle M, Poremba Ch, Nitz U, Harbeck N: Y-Box-Binding Protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J ClinOncol 2009, 27, 6144–6151.
  28. Rushmere NK, Knowlden JM, Gee JM, Harper ME, Robertson JF, Morgan BP, Nicholson RI: Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int J Cancer 2004, 108, 930–936.
  29. Maciejczyk A, Szelachowska J, Szynglarewicz B, Szulc R, Szulc A, Wysocka T, Jagoda E, Lage H, Surowiak P: CD46 expression is an unfavorable prognostic factor in breast cancer cases. Appl Immunohistochem Mol Morphol. 2011, 19, 540–546.
  30. Seghal P: Epigenetic control of activity manifested by STAT3 transcription factor in neoplastic cells [in Polish]. Współ Onkol 2006, 10, 8, 373–377.
  31. Buettner R, Huang M, Gritsko T, Karras J, Enkemann S, Mesa T, Nam S, Yu H, Jove R: Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol Cancer Res 2007, 5(8), 823–832.
  32. Salama I, Malone PS, Mihaimeed F, Jones JL: A review of the S100 proteins in cancer. Eur J Surg Oncol 2008 Apr, 34(4), 357–3564.
  33. McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ: The role of S100 genes in breast cancer progression. Tumour Biol 2011 Jun, 32(3), 441–450.
  34. Cancemi P, Di Cara G, Albanese NN, Costantini F, Marabeti MR, Musso R, Lupo C, Roz E, Pucci-Minafra I: Large-scale proteomic identification of S100 proteins in breast cancer tissues. BMC Cancer 2010, 10, 476.
  35. Maciejczyk A, Szelachowska J, Ekiert M, Matkowski R, Hałoń A, Lage H, Surowiak P: Elevated nuclear YB1 expression is associated with poor survival of patients with early breast cancer. Anticancer Res 2012, 32, 8, 3177– 3184.
  36. Győrffy B, Benke Z, Lánczky A, Balázs B, Szállási Z, Timár J, Schäfer R: RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat 2012, 132, 3, 1025–1034.
  37. Győrffy B, Lánczky A,Eklund A, Denkert C, Budczies J, Li Q, Szállási Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010, 123, 725–773.